Osteoporosis treatment via programmed delivery of IRF5 siRNA to macrophages in bone tissue combined with ROS scavenging.
- 1Department of Orthopedics, The Chinese PLA General Hospital & National Clinical Research Center for Orthopedics, Sports Medicine and Rehabilitation, China.
- 2School of Life Sciences, Tsinghua University, China.
- 3Central Laboratory, Tianjin Stomatological Hospital, School of Medicine, Nankai University & Tianjin Key Laboratory of Oral and Maxillofacial Function Reconstruction & Stomatology Institute of Nankai University, China.
Abstract
Postmenopausal osteoporosis (PO) is not merely a consequence of increased osteoclast activity. Estrogen deficiency induces oxidative stress and pro-inflammatory M1 macrophage polarization in bone tissue, thereby sustaining osteoclastogenic stimuli and pathological bone resorption. Interferon regulatory factor 5 (IRF5) is a key regulator of M1 polarization, and silencing its gene by small interfering RNA (siIRF5) may attenuate the pathogenesis of PO. However, selective delivery of siIRF5 to M1 macrophages within the osteoporotic bone microenvironment is challenging. Herein, we develop a nanomedicine, termed siP@WM, for programmed sequential targeting of bone tissue and macrophages. The siP@WM integrates a platinum nanozyme core with mesoporous silica shell loading siIRF5. The shell with enlarged pores (10-15 nm) provides effective siRNA encapsulation and programmable surface grafting of two kinds of poly(ethylene glycol) (PEG) derivatives. The longer poly(aspartic acid)-terminated PEG chain promotes bone enrichment. ROS-triggered thioketal cleavage shortens this chain, reduces bone-matrix adhesion, and exposes the shorter folic acid-functionalized PEG chain to enhance M1 macrophage uptake. In vitro, siP@WM scavenges ROS, facilitates endosomal escape, achieves approximately 60% IRF5 knockdown, and promotes M2 polarization. In ovariectomized mice, systemic administration of siP@WM ameliorates bone loss, restores trabecular microarchitecture and mechanical strength, and shows no overt short-term toxicity in major organs. Transcriptomic and histological analyses support attenuated AP-1-associated inflammatory signaling, suppressed osteoclast differentiation, and modulated extracellular matrix remodeling. Together, programmed siIRF5 delivery to macrophages in bone tissue combined with ROS scavenging restores bone homeostasis and provides an adaptive biomaterial strategy for PO treatment.
Related
- Engineering exosomes-mediated RNA delivery regulates bone homeostasis and alleviates osteoporosis.
- Epigenetic regulatory networks in the pathogenesis and treatment of osteoporosis subtypes.
- Bone-targeting engineered exosomes delivering teriparatide mRNA for the treatment of osteoporosis.
- Exosome based nanocarriers enabling effective treatment of antimicrobial resistant infections through improved delivery and clinical potential
- Unraveling the Promising Role of Phytochemical-Based Therapies and Their Novel Delivery Systems in the Prevention and Treatment of Oral Diseases
BibTeX
@article{chen2026osteoporosis,
title = {{Osteoporosis treatment via programmed delivery of IRF5 siRNA to macrophages in bone tissue combined with ROS scavenging.}},
author = {Zining Chen and Jinjin Wu and Yunyan Zhu and Anqi Tan and Junhao Deng and Yuting Niu and Weiran Li and Yunfei Zheng},
journal = {Bioactive materials},
year = {2026},
month = oct,
doi = {10.1016/j.bioactmat.2026.10.015},
url = {https://europepmc.org/article/MED/42926849},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Osteoporosis treatment via programmed delivery of IRF5 siRNA to macrophages in bone tissue combined with ROS scavenging.
AU - Zining Chen
AU - Jinjin Wu
AU - Yunyan Zhu
AU - Anqi Tan
AU - Junhao Deng
AU - Yuting Niu
AU - Weiran Li
AU - Yunfei Zheng
PY - 2026
DA - 2026/10/14
JO - Bioactive materials
DO - 10.1016/j.bioactmat.2026.10.015
UR - https://europepmc.org/article/MED/42926849
AB - Postmenopausal osteoporosis (PO) is not merely a consequence of increased osteoclast activity. Estrogen deficiency induces oxidative stress and pro-inflammatory M1 macrophage polarization in bone tissue, thereby sustaining osteoclastogenic stimuli and pathological bone resorption. Interferon regulatory factor 5 (IRF5) is a key regulator of M1 polarization, and silencing its gene by small interfering RNA (siIRF5) may attenuate the pathogenesis of PO. However, selective delivery of siIRF5 to M1 macrophages within the osteoporotic bone microenvironment is challenging. Herein, we develop a nanomedicine, termed siP@WM, for programmed sequential targeting of bone tissue and macrophages. The siP@WM integrates a platinum nanozyme core with mesoporous silica shell loading siIRF5. The shell with enlarged pores (10-15 nm) provides effective siRNA encapsulation and programmable surface grafting of two kinds of poly(ethylene glycol) (PEG) derivatives. The longer poly(aspartic acid)-terminated PEG chain promotes bone enrichment. ROS-triggered thioketal cleavage shortens this chain, reduces bone-matrix adhesion, and exposes the shorter folic acid-functionalized PEG chain to enhance M1 macrophage uptake. In vitro, siP@WM scavenges ROS, facilitates endosomal escape, achieves approximately 60% IRF5 knockdown, and promotes M2 polarization. In ovariectomized mice, systemic administration of siP@WM ameliorates bone loss, restores trabecular microarchitecture and mechanical strength, and shows no overt short-term toxicity in major organs. Transcriptomic and histological analyses support attenuated AP-1-associated inflammatory signaling, suppressed osteoclast differentiation, and modulated extracellular matrix remodeling. Together, programmed siIRF5 delivery to macrophages in bone tissue combined with ROS scavenging restores bone homeostasis and provides an adaptive biomaterial strategy for PO treatment.
SN - 2452-199X
ER -